个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Libo Yang[1,2] ; Feng Ye[2] ; Longlong Bao[3,4,5] ; Xiaoyan Zhou[3,4,5] ; Zhe Wang[6] ; Peizhen Hu[6] ; Nengtai Ouyang[7] ; Xiaojuan Li[7] ; Yi Shi[8] ; Gang Chen[8] ; Peiyi Xia[9,10] ; Meiying Chui[9,10] ; Wencai Li[9,10] ; Ying Jia[11] ; Yueping Liu[11] ; Junjun Liu[12] ; Junyi Ye[12] ; Zhe Zhang[12] ; Hong Bu[1,2,*1] ;
机构： [1]Department of Pathology, West China,Hospital of Sichuan University, Chengdu, China [2]Laboratory of Pathology, West China,Hospital of Sichuan University, Chengdu, China [3]Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China [4]Department of Oncology, Shanghai Medical College, Shanghai, China [5]Institute of Pathology, Fudan University, Shanghai, China [6]Department of Pathology, Xijing Hospital and School of Basic Medicine, Air Force Medical University, Xi'an, China [7]Cellular & Molecular Diagnostics Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China [8]Department of Molecular Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China [9]Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [10]Department of Pathology, School of Basic Medicine, Zhengzhou University, Zhengzhou, China [11]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [12]Burning Rock Biotech, Guangzhou, China
出处：
DOI： 10.1111/cas.13976
ISSN：

关键词： breast neoplasm genetic variation high-throughput nucleotide sequencing neoadjuvant therapy pathologic complete response

摘要：
The correlation of genetic alterations with response to neoadjuvant chemotherapy (NAC) has not been fully revealed. In this study, we enrolled 247 breast cancer patients receiving anthracycline-taxane-based NAC treatment. A next generation sequencing (NGS) panel containing 36 hotspot breast cancer-related genes was used in this study. Two different standards for the extent of pathologic complete response (pCR), ypT0/isypN0 and ypT0/is, were used as indicators for NAC treatment. TP53 mutation (n = 149, 60.3%), PIK3CA mutation (n = 109, 44.1%) and MYC amplification (n = 95, 38.5%) were frequently detected in enrolled cases. TP53 mutation (P = 0.019 for ypT0/isypN0 and P = 0.003 for ypT0/is) and ERBB2 amplification (P < 0.001 for both ypT0/isypN0 and ypT0/is) were related to higher pCR rates. PIK3CA mutation (P = 0.040 for ypT0/isypN0) and CCND2 amplification (P = 0.042 for ypT0/is) showed reduced sensitivity to NAC. Patients with MAPK pathway alteration had low pCR rates (P = 0.043 for ypT0/is). Patients with TP53 mutation (-) PIK3CA mutation (-) ERBB2 amplification (+) CCND1 amplification (-), TP53 mutation (+) PIK3CA mutation (-) ERBB2 amplification (+) CCND1 amplification (-) or TP53 mutation (+) PIK3CA mutation (+) ERBB2 amplification (+) CCND1 amplification (-)had significantly higher pCR rates (P < 0.05 for ypT0/isypN0 and ypT0/is) than wild type genotype tumors. Some cancer genetic alterations as well as pathway alterations were associated with chemosensitivity to NAC treatment. Our study may shed light on the molecular characteristics of breast cancer for prediction of NAC expectations when breast cancer is first diagnosed by biopsy. © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

基金：
Research Supporting Project from Science and Technology Department of Sichuan Province, Grant/Award Number: 2017SZ0005; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, Grant/Award Number: ZYGD18012; Fujian Provincial Science and Technology Department Planning Project, Grant/Award Number: 2018Y2003
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2019]版：
Q2 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Department of Pathology, West China,Hospital of Sichuan University, Chengdu, China [2]Laboratory of Pathology, West China,Hospital of Sichuan University, Chengdu, China
通讯作者：
通讯机构： [1]Department of Pathology, West China,Hospital of Sichuan University, Chengdu, China [2]Laboratory of Pathology, West China,Hospital of Sichuan University, Chengdu, China [*1]Department of Pathology, West China Hospital of Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714)：
Libo Yang,Feng Ye,Longlong Bao,et al.Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.[J].CANCER SCIENCE.2019,110(4):1389-1400.doi:10.1111/cas.13976.
APA：
Libo Yang,Feng Ye,Longlong Bao,Xiaoyan Zhou,Zhe Wang...&Hong Bu.(2019).Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers..CANCER SCIENCE,110,(4)
MLA：
Libo Yang,et al."Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.".CANCER SCIENCE 110..4(2019):1389-1400

相关文献

[1]Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer [2]Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer [3]CT Radiomics based on Machine Learning Predicting Pathologic Complete Response after Neoadjuvant Chemoradiotherapy for Esophageal Cancer [4]Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer [5]Tumor-Infiltrating Lymphocytes Improve Magee Equation-Based Prediction of Pathologic Complete Response in HR-Positive/HER2-Negative Breast Cancer. [6]预测局部进展期直肠癌新辅助放化疗后病理完全缓解的临床因素研究 [7]CALGB 40603研究分析:Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率 [8]预测局部进展期直肠癌新辅助放化疗后病理完全缓解的临床因素研究 [9]Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. [10]Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy

资源点击量：46420 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号